Printer Friendly

Arthritis protection could hold key to Alzheimer's drug.

RHEUMATOID arthritis sufferers have a built-in protection against Alzheimer's that could soon become a promising new treatment for the brain disease, it was revealed yesterday.

The protein GM-CSF plays a role in the defective immune system response that leads to the arthritic disorder.

But it also marshals the immune system to remove harmful deposits in the brain that are linked to Alzheimer's.

Tests on mice showed that the protein could reverse Alzheimer's symptoms in just 20 days.

Scientists, who say they are "amazed" at the finding, believe the discovery could quickly lead to a practical new treatment for Alzheimer's, the most common form of dementia.

A laboratory-made version of GM-CSF called Leukine has been used for years to boost the immune systems of certain cancer patients.

Because its safety profile is already well known, it should not take long to convert into an Alzheimer's therapy.

The US scientists, from the Health Byrd Alzheimer's Institute at Florida State University, are now planning a pilot trial later this year that will put the theory to the test.

Patients with mild or moderate levels of Alzheimer's will be given the protein to see if their symptoms improve.

Lead researcher Professor Huntington Potter said: "Our study, along with the drug's track record for safety, suggests Leukine should be tested in humans as a potential treatment for Alzheimer's disease."

It was already known that people with rheumatoid arthritis (RA), an auto-immune disease that attacks the joints, had a reduced risk of Alzheimer's.

Until recently, most experts assumed this was due to the anti-inflammatory drugs commonly given toRAsufferers. But recent clinical trials showed the drugs do not help Alzheimer's patients, putting the theory in doubt.

Prof Potter's team took a different tack by investigating immune system mechanisms in RA.

"Our findings provide a compelling explanation for why rheumatoid arthritis is a negative risk factor for Alzheimer's disease," said the professor, whose research was published online in the Journal of Alzheimer's Disease.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Western Mail (Cardiff, Wales)
Date:Aug 24, 2010
Previous Article:A matter of Recorde his invention = a symbol everyone could count on; TOWN CELEBRATES BIRTH IN 1510 OF MATHEMATICS GENIUS.
Next Article:Delays in home care left man in hospital two years.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters